Group A will include patients with accessible solid tumors and lymphomas. This group will receive a fixed dose of PDR001 i.v. on day 1 of every 28 day cycle and intratumoral injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle. Group B will include patients with accessible solid tumors and lymphomas. This group will receive a fixed dose of PDR001 i.v. on day 1 of every cycle and an intratumoral injection of MIW815 (ADU-S100) on day 1 of every cycle.